Amgen Inc (AMGN) reported better-than-expected financial results for the third quarter of fiscal 2025. The company achieved earnings per share (EPS) of $5.64, surpassing Wall Street's consensus estimate of $5.11 by $0.53. Revenue also exceeded expectations, reaching $9.6 billion compared to the anticipated $9.1 billion.
The announcement highlights Amgen's robust operational performance and financial health, reflecting its commitment to addressing high unmet medical needs through human therapeutics. The company, headquartered in Thousand Oaks, California, employs 28,000 full-time staff and markets a diverse portfolio of therapeutics, including ENBREL, Otezla, and Repatha.
Amgen will host its earnings conference call at 4:00 PM (AMC) to discuss these results further and provide additional insights into its business performance.
Investors may wish to review the full earnings release and listen to management commentary for context on the quarter's performance and future outlook. Amgen's market capitalisation stands at $169,939.12 million, with a price-to-earnings ratio (P/E) of 24.26 and a trailing EPS of 12.94. The company anticipates upcoming earnings on 2 August 2026, with estimates of EPS at 5.7105 and revenue at $9.4 billion.